Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:30:47.254Z.
Calculation as of: 2026-10-06T13:30:47.254Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ee881eee59918e8cff759d9372c22030baed04f147f6b571d3011c58a892a573
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$88.21M
EV/EBIT Ratio
23.74x
TTM Avg
34.08x
3Y Avg
34.41x
5Y Avg
73.74x
Market Cap
$99.01M
EV/EBIT Ratio
N/A
TTM Avg
28.81x
3Y Avg
28.81x
5Y Avg
28.81x
Market Cap
$85.60M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | $92.54M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $92.41M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $88.97M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 23.74x | 34.08x | 34.41x | 73.74x |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 13.68x | 11.03x | 8.69x | 166.50x |
| Equillium, Inc. (EQ)vs › | $87.88M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $99.01M | N/A | 28.81x | 28.81x | 28.81x |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.79M | N/A | 10.94x | 10.94x | 10.94x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
